<DOC>
	<DOC>NCT02435914</DOC>
	<brief_summary>This study will evaluate the safety, efficacy, tolerability, and systemic pharmacokinetics of 3 different doses of topical ophthalmic AGN-223575 suspension compared to AGN-223575 vehicle in patients with dry eye disease.</brief_summary>
	<brief_title>Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Signs and symptoms of dry eye disease Has used RESTASIS and/or artificial tears in both eyes twice a day for at least 60 days. History of glaucoma, or ocular hypertension Diagnosis of ocular infection Use of contact lenses in the past 14 days or expected use during the study Use of any topical ophthalmic medications in the past 30 days Use of corticosteroids in the past 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>